Home>>Signaling Pathways>> Neuroscience>> iGluR>>CX 717

CX 717

Catalog No.GC64244

CX 717 is a positive allosteric modulator of AMPA receptor.

Products are for research use only. Not for human use. We do not sell to patients.

CX 717 Chemical Structure

Cas No.: 867276-98-0

Size Price Stock Qty
5 mg
$43.00
In stock
10 mg
$72.00
In stock
50 mg
$225.00
In stock
100 mg
$360.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

CX 717 is a positive allosteric modulator of AMPA receptor. Antidepressant-like effect. CX 717 can be used for the research of adult attention deficit hyperactivity disorder (ADHD)[1][2].

CX 717 (CX717; 20 mg/kg) has a rapid (30 min) but short-lasting (up to 24 h) antidepressantlike effect in the forced swim test.CX 717 also produces a rapid (up to 1 h) increase of brain-derived neurotrophic factor (BDNF) and a more sustained (up to 6 h) increase of p11[2]. Intra-cortical infusion of CX 717 (85 mM) increases the efflux of noradrenaline, dopamine, and serotonin, but not glutamate[2].

[1]. Linda J Porrino, et al. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol. 2005 Sep;3(9):e299.
[2]. Marta Gordillo-Salas, et al. Antidepressant-Like Effects of CX717, a Positive Allosteric Modulator of AMPA Receptors. Mol Neurobiol. 2020 Aug;57(8):3498-3507.

Reviews

Review for CX 717

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CX 717

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.